Egis Gyogyszergyar Rt.

Zsuzsa Szent Kirallyi

Gyula Simig

Jozsef Barkoczy

Kalman Nagy

Peter Kotay Nagy

Laszlo Balazs

Ferenc Lorant Bartha

Zoltan Ratkai

Peter Seres

Imre Doman

Györgyi Vereczkeyne Donath

Ferenc Barta

Gyorgyi Vereczkeyne Donath

The invention relates to new crystalline forms I and II of (4R-cis)-6-[2-[3-phenyl-4-(phenyl-carbamoyl)-2-(4-fluoro-phenyl)-5-(1- methyl-ethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]dioxane-4-yl-acetic acid-tertiary butyl ester of the Formula (I) and a process for the preparation thereof. The new polymorphs of the present invention are useful pharmaceutical intermediates which can be used in the preparation of the hydroxymethyl-glutaryl coenzyme (HMG-COA) reducing enzyme inhibitor having the INN (International Non-proprietory Name) atorvastatin 

Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin

The invention relates to a process for the preparation of amorphous atorvastatin calcium by recrystallization of crude atorvastatin from an organic solvent which comprises dissolving crude amorphous atorvastatin calcium in a lower alkanol containing 2-4 carbon atoms or a mixture of such alkanols under heating and isolating the amorphous atorvastatin calcium precipitated after cooling. The atorvastatin calcium obtained is a known valuable agent useful in treating hyperlipidemia and hypercholestrolemia.

Process for the preparation of amorphous atorvastatin calcium

Growing community of inventors

Budapest, Hungary

Zsuzsa Szent Kirallyi